Biomarker Testing and Treatment Strategies in HER2-Overexpressing NSCLC

home / oncview / biomarker-testing-and-treatment-strategies-in-her2-overexpressing-nsclc

Panelists discuss how advancements in biomarker testing and targeted therapies, particularly trastuzumab deruxtecan, are reshaping treatment strategies for HER2-overexpressing non-small cell lung cancer.

An Overview of HER2 Alterations in NSCLC and Implications for Treatment

EP. 1: An Overview of HER2 Alterations in NSCLC and Implications for Treatment

Rohit Gosain, MD;Rahul Gosain, MD;Benjamin P. Levy, MD
November 8th 2024

Panelists discuss how understanding the distinctions between HER2 overexpression and mutations in NSCLC influences patient care strategies and prognosis, alongside the challenges of biomarker testing methods such as IHC and NGS.